Arena Pharmaceuticals Inc.
Description Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the companys preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California. To view the detailed information, you need to SUBSCRIBE with us. |
 |